TY - JOUR AB - For over three decades, methionine aminopeptidase 2 (MetAP2) has been a tentative drug target for the treatment of cancer, obesity, and autoimmune diseases. Currently, no MetAP2 inhibitors (MetAP2i) have reached the clinic yet, despite considerable investment by major pharmaceutical companies. Here, we summarize the key series of MetAP2i developed to date and discuss their clinical development, progress, and issues. We coalesce the currently disparate knowledge regarding MetAP2i mechanism of action and discuss discrepancies across varied studies. Finally, we highlight the current knowledge gaps that need to be addressed to enable successful development of MetAP2 inhibitors in clinical settings. AU - Goya,Grocin A AU - Kallemeijn,W AU - Tate,E DO - 10.1016/j.tips.2021.07.004 EP - 882 PY - 2021/// SN - 0165-6147 SP - 870 TI - Targeting methionine aminopeptidase 2 in cancer, obesity and autoimmunity T2 - Trends in Pharmacological Sciences UR - http://dx.doi.org/10.1016/j.tips.2021.07.004 UR - http://hdl.handle.net/10044/1/102175 VL - 42 ER -